Crystal Lake, Illinois, April 3, 2020 - AptarGroup, Inc. (NYSE: ATR), a global leader in drug
delivery, consumer product dispensing and active
packaging solutions, is seeking U.S. FDA Emergency
Use Authorization (EUA) for a solution that allows easy
disinfecting of N95 filtering facepiece respirators (N95
mask). The N95 masks are desperately needed by
healthcare personnel due to the shortage of disposable
masks during the COVID-19 pandemic.
In this simple disinfecting process, the N95 mask and a
Photo: N95 Mask Decontamination with ActivShieldTM by Aptar
small strip of Aptar’s ActivShieldTM are placed inside any commonly available one-gallon plastic
bag. The strip releases a controlled amount of chlorine dioxide inside the sealed bag to
decontaminate the N95 mask. The process takes only three hours until the mask is ready to
wear again. It can be performed on-site at the local hospital where the mask is being used.
Aptar has submitted its safety and effectiveness data to the FDA for EUA review. The company
is working to provide approximately four million ActivShield strips per week and is working to
expand its production capacity with the intent to deliver ten million per week by the end of April.
“We are extremely encouraged by the promising data generated so far and are eager to deliver
this technology to the front line and support the fight against the pandemic,” said John Belfance,
President of Aptar CSP Technologies. If the FDA approves the EUA, then ActivShield will
immediately become available for this important use.
Chlorine dioxide has been widely used as a disinfectant in different industries, including the
paper industry, drinking water treatment, food processing, and medical equipment. Aptar’s
delivery mechanism uses the disinfecting properties of chlorine dioxide in a controlled sustained
release within a contained volume.
This innovative patent pending technology can efficiently and effectively disinfect N95 masks
used by healthcare workers and first responders.
“Aptar’s technology provides a unique, simple, and effective way to help solve the critical
problem of PPE shortages we’re currently facing,” said Stephan Tanda, Aptar President and
CEO. “We are aiming to provide a solution that is not only fast, but it does not require special
equipment or training, making it potentially accessible to the wider healthcare community. This
could enable healthcare workers to retain and disinfect their own facemask, helping to maintain
continued proper fit to their face.”
About Aptar
Aptar is a global leader in the design and manufacturing of a broad range of drug delivery,
consumer product dispensing and active packaging solutions. Aptar uses insights, design,
engineering and science to create dosing, dispensing and protective packaging technologies for
the world’s leading brands, in turn making a meaningful difference in the lives, looks, health and
homes of millions of people around the world. Aptar’s innovative solutions and services serve a
variety of end markets including pharmaceutical, beauty, personal care, home, food and
beverage. The company is headquartered in Crystal Lake, Illinois and has 14,000 dedicated
employees in 20 countries. For more information, visit www.aptar.com.
This press release contains forward-looking statements. Words such as “promising” or “working” and other similar
expressions or future or conditional verbs such as “will” or “could” are intended to identify such forward-looking statements. Forward-
looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently
available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking
statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but
not limited to: economic conditions worldwide; uncertainties related to the timing or outcome of product development; the regulatory
environment; and competition, including technological advances. For additional information on these and other risks and
uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs.
We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or
otherwise.
# # #
Product Contact:
Corporate Contact:
John Belfance Matt DellaMaria
john.belfance@aptar.com
matt.dellamaria@aptar.com
518-469-3358
815-479-5530
John Belfance
john.belfance@aptar.com
5184693358
